Immunotherapy of sepsis

Lancet Infectious Diseases

Volumn 1, Issue 3, 2001, Pages 165-174

  Van Der Poll, Tom ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIINFLAMMATORY AGENT; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN;

ANIMAL; CLINICAL TRIAL; FORECASTING; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; REVIEW; SEPSIS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTICOAGULANTS; CLINICAL TRIALS; CYTOKINES; FORECASTING; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOTHERAPY; SEPSIS;

EID: 0035495804     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(01)00093-7     Document Type: Review

References (81)

1. ACCP-SCCM Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20: 864-74.
2. Van der Poll T., van Deventer S.J.H. Cytokines and anticytokines in the pathogenesis of sepsis. Infect Dis Clin North Am. 13:1999;413-426.
3. Freeman B.D., Natanson C. Anti-inflammatory therapies in sepsis and septic shock. Expert Opin Investig Drugs. 9:2000;1651-1663.
4. Volk H.D., Reinke P., Döcke W.D. Clinical aspects: from systemic inflammation to "immunoparalysis" Chem Immunol. 74:2000;162-177.
5. Lowry S.F., Calvano S.E., van der Poll T. Measurement of inflammatory mediators in clinical sepsis. Sibbald W.J., Vincent J.L. Clinical trials for the treatment of sepsis. 1995;86-105 Springer-Verlag, New York.
6. Beutler B., Milsark I.W., Cerami A. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 229:1985;869-871.
7. Tracey K.J., Fong Y., Hesse D.G., et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature. 330:1987;662-664.
8. Ohlsson K., Björk P., Bergenfeldt M., Hageman R., Thompson R.C. Interleukin 1 receptor antagonist reduces mortality from endotoxin shock. Nature. 348:1990;550-552.
9. Fischer E., Marano M.A., van Zee K.J., et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest. 89:1992;1551-1557.
10. Tracey K.J., Beutler B., Lowry S.F., et al. Shock and tissue injury induced by recombinant human cachectin. Science. 234:1986;470-474.
11. Okusawa S., Gelfland J.A., Ikejima T., Connolly R.J., Dinarello C.A. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest. 81:1988;1162-1172.
12. Marchant A., Bruyns C., Vandenabeele P., et al. IL-10 controls IFN-γ and TNF production during experimental endotoxemia. Eur J Immunol. 24:1994;1167-1171.
13. Berg D.J., Kühn R., Rajewsky K., et al. Interleukin-10 is a central regulator of the response to LPS in murine models of endotoxic shock and the Shwartzman reaction but not endotoxin tolerance. J Clin Invest. 96:1995;2339-2347.
14. Marshall J.C. Clinical trials of mediator-directed therapy in sepsis: what have we learned? Intensive Care Med. 26:2000;S75-S83.
15. Angus D.C., Birmingham M.C., Balk R.A., et al. E5 Study Investigators. E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis. JAMA. 283:2000;1723-1730.
16. Bennett I.L., Finland M., Hamborger M., Kass E.H., Lepper M., Waisbren B.A. The effectiveness of hydrocortisone in the management of severe infection. JAMA. 183:1963;462-465.
17. Lefering R., Neugebauer E.A.M. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. 23:1995;1294-1303.
18. Zeni F., Freeman B.D., Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. Crit Care Med. 25:1997;1095-1100.
19. Bollaert P.E., Charpentier C., Levy B., Debouverie M., Audiberst G., Larcan A. Reversal of late septic shock with supraphysiological doses of hydrocortisone. Crit Care Med. 26:1998;645-650.
20. Briegel J., Forst H., Haller M., et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single center study. Crit Care Med. 27:1999;723-732.
21. Annane D. Effects of the combination of hydrocortisone (HC)-fludro-cortisone (FC) on mortality in septic shock. Crit Care Med. 28:(suppl. 12):2000;A46.
22. Lynn W.A. Anti-endotoxin-therapeutic options for the treatment of sepsis. J Antimicrob Chemother. 41:(suppl. A):1998;71-80.
23. Ziegler E.J., McCutchan J.A., Fierer J., et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med. 307:1982;1225-1230.
24. Ziegler E.J., Fisher C.J., Sprung C.L., et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl J Med. 324:1991;429-436.
25. Pajkrt D., Doran J.E., Koster F., et al. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med. 184:1996;1601-1608.
26. Von der Möhlen M.A.M., Kimmings A.N., Wedel N.I., et al. Inhibition of endotoxin-induced cytokine release and neutrophil activation in humans by use of recombinant bactericidal/permeability-increasing protein. J Infect Dis. 172:1995;144-151.
27. Levin M., Quint P.A., Goldstein B., et al. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. Lancet. 356:2000;961-967.
28. Arndt P., Abraham E. Immunological therapy of sepsis: experimental therapies. Intensive Care Med. 27:2001;S104-115.
29. Fisher C.J., Agosti J.M., Opal S.M., et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med. 334:1996;1697-1702.
30. Panacek E., Marshall J., Fischkoff S., et al. Neutralization of TNF by a monoclonal antibody improves survival and reduces organ dysfunction in human sepsis: results of the MONARCS trial. (abstr). Chest. 118:(suppl. 4):2000;88S.
31. Dehoux M.S., Boutten A., Ostinelli J., et al. Compartmentalized cytokine production within the human lung in unilateral pneumonia. Am J Respir Crit Care Med. 150:1994;710-716.
32. Fröhlich D., Eiber R.M., Jochum M., Billing A. Perioperative pattern of peritoneal interleukin 8, tumour necrosis factor-α, and granulocyte elastase release in human secondary peritonitis. Cytokine. 9:1997;288-292.
33. Laichalk L.L., Kunkel S.L., Strieter R.M., Danforth J.M., Bailie M.B., Standiford T.J. Tumor necrosis factor mediates lung antibacterial host defense in murine Klebsiella pneumonia. Infect Immun. 64:1996;5211-5218.
34. Van der Poll T., Keogh C.V., Buurman W.A., Lowry S.F. Passive immunization against tumor necrosis factor alpha impairs host defense during pneumococcal pneumonia. Am J Resp Crit Care Med. 155:1997;603-608.
35. Greenberger M.J., Strieter R.M., Kunkel S.L., Danforth J.M., Goodman R.E., Standiford T.J. Neutralization of IL-10 increases survival in a murine model of Klebsiella pneumonia. J Immunol. 155:1995;722-729.
36. Van der Poll T., Marchant A., Keogh C.V., Goldman M., Lowry S.F. Interleukin-10 impairs host defense in murine pneumococcal pneumonia. J Infect Dis. 174:1996;994-1000.
37. Echtenacher B., Falk W., Mannel D.N., Krammer P.H. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol. 145:1990;3762-3766.
38. Sewnath M.E., Olszyna D.P., Birjmohun R.S., ten Kate F.J.W., Gouma D.J., van der Poll T. Interleukin 10 deficient mice demonstrate multiple organ failure and increased mortality during Escherichia coli peritonitis in spite of an accelerated bacterial clearance. J Immunol. 166:2001;6323-6331.
39. Munoz C., Carlet J., Fitting C., Misset B., Blériot J.P., Cavaillon J.M. Dysregulation of in vitro cytokine production by monocytes during sepsis. J Clin Invest. 88:1991;1747-1754.
40. Van Deuren M., van der Ven-Jongekrijg H., Demacker P.N.M., et al. Differential expression of proinflammatory cytokines and their inhibitors during the course of meningococcal infections. J Infect Dis. 169:1994;157-161.
41. McCall C.E., Grosso-Wilmoth L.M., LaRue K., Guzman R.N., Cousart S.L. Tolerance to endotoxin-induced expression of the interleukin-1α gene in blood neutrophils of humans with the sepsis syndrome. J Clin Invest. 91:1993;853-861.
42. Marie C., Muret J., Fitting C., Losser M.R., Payen D., Cavaillon J.M. Reduced ex vivo interleukin-8 production by neutrophils in septic and non-septic systemic inflammatory response syndrome. Blood. 91:1998;3439-3446.
43. Ertel W., Keel M., Neidhardt R., et al. Inhibition of the defense system stimulating interleukin-12 interferon-a pathway during critical illness. Blood. 89:1997;1612-1620.
44. Brandtzaeg P., Osnes L., Ovstebo R., Joo G.B., Westwik A.B., Kierulf P. Net inflammatory capacity of human septic shock plasma evaluated by a monocyte-based target cell assay: identification of interleukin-10 as a major functional deactivator of human monocytes. J Exp Med. 184:1996;51-60.
45. Ayala A., Knotts J.B., Ertel W., Perrin M.M., Morrison M.H., Chaudry I.H. Role of interleukin 6 and transforming growth factor-beta in the induction of depressed splenocyte responses following sepsis. Arch Surg. 128:1993;89-94.
46. Van der Poll T., Coyle S.M., Barbosa K., Braxton C.C., Lowry S.F. Epinephrine inhibits tumor necrosis factor and potentiates interleukin 10 release during human endotoxemia. J Clin Invest. 97:1996;713-719.
47. Van der Poll T., Barber A.E., Coyle S.M., Lowry S.F. Hypercortisolemia increases plasma interleukin 10 concentrations during human endotoxemia. J Clin Endocrin Metab. 81:1996;3604-3606.
48. Choudhry M.A., Ahmad S., Ahmed Z., Sayeed M.M. Prostaglandin E2 down-regulation of T cell IL-2 production is independent of IL-10 during Gram-negative sepsis. Immunol Lett. 67:1999;125-130.
49. Döcke W.D., Randow F., Syrbe U., et al. Monocyte deactivation in septic patients: restoration by IFN-γ treatment. Nat Med. 3:1997;678-681.
50. Bilgin K., Yaramis A., Haspolat K., Tas M.A., Gunbey S. A randomized trial of granulocyte-macrophage colony-stimulating factor in neonates with sepsis and neutropenia. Pediatrics. 107:2001;36-41.
51. Root R.K., Dale D.C. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor: comparisons and potential for use in the treatment of infections of nonneutropenic patients. J Infect Dis. 179:1999;S342-352.
52. Hartung T., Döcke W.D., Gantner F., et al. Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood. 85:1995;2482-2489.
53. Van der Poll T. The use of granulocyte colony-stimulating factor in critically ill patients. Crit Care Med. 28:2000;3758-3759.
54. Nelson S., Heyder A.M., Stone J., et al. A randomized controlled trial of filgrastim for the treatment of hospitalized patients with multilobar pneumonia. J Infect Dis. 182:2000;970-973.
55. Miura E., Procianoy R.S., Bittar C., et al. A randomized, double-masked, placebo-controlled trial of recombinant granulocyte colony-stimulating factor administration to preterm infants with the clinical diagnosis of early-onset sepsis. Pediatrics. 107:2001;30-35.
56. Kaul R., McGeer A., Norrby-Teglund A., et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. Clin Infect Dis. 28:1999;800-807.
57. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulins for treating sepsis and septic shock. Cochrane Database Syst Rev 2001; 2: CD001090.
58. Levi M., ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 341:1999;586-592.
59. Taylor F.B. Jr, Chang A., Ruf W., et al. Lethal E coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock. 33:1991;127-134.
60. Creasey A.A., Chang A.C.K., Feigen L., Wün T.C., Taylor F.B. Jr, Hinshaw L.B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest. 91:1993;2850-2860.
61. Taylor F.B. Jr, Chang A.C.K., Peer G.T., et al. DEGR-factor Xa blocks disseminated intravascular coagulation initiated by Escherichia coli without preventing shock or organ damage. Blood. 78:1991;364-368.
62. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med. 28:2000;S31-33.
63. Dickneite G. Antithrombin III in animal models of sepsis and organ failure. Semin Thromb Haemostas. 24:1998;61-69.
64. Eisele B., Lamy M., Thijs B., et al. Antithrombin III in patients with severe sepsis: a randomized, placebo-controlled, double-blind, multicenter trial, plus a meta-analysis on all randomized-placebo-controlled, double-blind trials with antithrombin III in severe sepsis. Intensive Care Med. 24:1998;663-672.
65. Inthorn D., Hoffmann J.N., Harti W.H., Mühlbayer D., Jochum M. Effect of antithrombin III supplementation on inflammatory response in patients with severe sepsis. Shock. 10:1998;90-96.
66. Esmon C.T. New potential therapeutic modalities: aPC. Sepsis. 3:1999;161-171.
67. Matthay M.A. Severe sepsis. A new treatment with both anticoagulant and antiinflammatory properties. N Engl J Med. 344:2001;759-761.
68. Taylor F.B. Jr, Chang A., Esmon T., D'Angelo A., Vigano-D'Angelo S., Blick K.E. Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest. 79:1987;918-925.
69. Taylor F.B. Jr, Stearns-Kurosawa J., Kurosawa S., et al. The endothelial cell protein C receptor aids in host defense against Escherichia coli sepsis. Blood. 95:2000;1680-1686.
70. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 344:2001;699-709.
71. Aderem A., Ulevitch R.J. Toll-like receptors in the induction of the innate immune response. Nature. 406:2000;782-787.
72. Hayashi F., Smith K.D., Ozinsky A., et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature. 410:2001;1099-1103.
73. Hemmi H., Takeuchi O., Kawai T., et al. A Toll-like receptor recognizes bacterial DNA. Nature. 408:2000;740-745.
74. Ozinsky A., Underhill D.M., Fontenot J.D., et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between Toll-like receptors. Proc Natl Acad Sci USA. 97:2000;13766-13771.
75. Takeuchi O., Hoshimo K., Akira S. TLR-2 deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol. 165:2000;5392-5396.
76. Wang H., Bloom O., Zhang M., et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science. 285:1999;248-251.
77. Kotzin B., Leung D., Kappler J., Marrack P. Superantigens andtheir potential role in human disease. Adv Immunol. 54:1993;99-166.
78. Llewelyn M., Cohen J. Superantigen antagonist peptides. Crit Care. 5:2001;53-55.
79. Kwiatkowski D. Genetic dissection of the molecular pathogenesis of infection. Intensive Care Med. 26:2000;S89-S97.
80. Westendorp R.G., Hottenga J.J., Slagboom P.E. Variation in plasminogen-activator-inhibitor-1 gene and risk of meningococcal septic shock. Lancet. 354:1999;561-563.
81. Arbour N.C., Lorenz E., Schutte B.C., et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet. 25:2000;187-191.